Financial Daily from THE HINDU group of publications
Saturday, Feb 07, 2004
News
Features
Stocks
Cross Currency
Shipping
Archives
Google

Group Sites

 Corporate - Alliances & Joint Ventures


Pfizer Sanofi pact to promote anti-depressant drug

Our Bureau

Mumbai , Feb. 6

PHARMA major Pfizer Ltd has entered into an agreement with Sanofi Synthelabo (India) Ltd for the co-promotion of Pfizer's anti-depressant product, Daxid.

The agreement is valid for a period of three years, the company told BSE. Daxid was launched in India in October 2002 and has sales of an estimated Rs 1.5 crore, industry analysts said.

Globally, Pfizer sells the product under the name Zoloft and it clocks revenues of about $3 billion, they said.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
FACT to hold EGM on Feb 27

TAFE to unveil 25 hp tractors soon; targets North
Radaan Media plans to forfeit partly-paid shares
MMTC declares 25 pc interim
Filatex shareholders okay preference share issue
India Inc not for restriction on pyramidal structure
L&T CMD Naik bags corporate leadership award
HMT wins award
HC stays warrant against Chennai co
Top-level attrition in Arvind Mills
Zee Telefilms plans to revamp debt portfolio
Ranbaxy to set up subsidiary in Spain
Cosmetics major L'Oréal opens Rs 50-cr manufacturing plant
Minda Huf to set up new plant in Pune
SEBI may amend norms for disclosing shareholding
Pfizer Sanofi pact to promote anti-depressant drug
`Our entry into regulated markets will show results next year'
Shiva Cement may raise Rs 9.5 cr through rights-cum-public issue
Thermax to focus on 50-100 MW range power plants
Mahindra Defence eyes Rs 100-crore turnover
Ashok Leyland sales up 30 pc in Jan

The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription
Group Sites: The Hindu | Business Line | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |

Copyright © 2004, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line